---
title: "CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296435690.md"
description: "CSPC PHARMA reported a 139.2% YoY surge in H1 2026 net profit to RMB6.094 billion, driven by a 56.7% rise in finished drug revenue and a massive 448.5% jump in licensing fees. Gross margin expanded to 76.2%. The company declared an interim dividend of HKD0.18 per share, up 28.6% YoY. While bulk product and functional food revenues declined, overall financial performance showed strong growth."
datetime: "2026-08-20T04:46:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296435690.md)
  - [en](https://longbridge.com/en/news/296435690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296435690.md)
generator: "portal-rs"
---

# CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18

CSPC PHARMA (01093.HK) +1.170 (+13.472%) Short selling $283.59M; Ratio 10.252% announced its interim results for the period ended June 2026. Revenue rose 40.1% YoY to RMB18.594 billion; net profit reached RMB6.094 billion, up 139.2% YoY; basic EPS was RMB0.5345. Under non-HKFRS, underlying profit amounted to RMB6.164 billion, up 165.8% YoY.  

The board declared an interim dividend of HKD0.18 per share, representing an increase of 28.6% from HKD0.14 in the corresponding period last year.

Interim gross profit margin reached 76.2%, up 10.6 ppts from 65.6% in the corresponding period last year, mainly driven by a higher contribution from the finished drug business.

In 1H26, CSPC PHARMA's finished drug business revenue amounted to RMB16.061 billion, up 56.7% YoY. Among which, licensing fee income surged 448.5% to RMB5.895 billion; revenue from bulk product business fell 20% YoY to RMB1.66 billion; revenue from functional food and other businesses decreased 8.2% to RMB873 million.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-20 12:25.)

AASTOCKS Financial News

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [UBS Raises CSPC PHARMA  TP to HKD11.8, Reiterates Buy](https://longbridge.com/en/news/296585459.md)
- [Citi Raises CSPC PHARMA  TP to HKD14, Rating Buy](https://longbridge.com/en/news/296566031.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**